Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Bethesda, Maryland, USA.
Neuroendocrine Tumors Service, The Chaim Sheba Medical Center, Tel HaShomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Endocr Relat Cancer. 2020 Jun;27(6):355-360. doi: 10.1530/ERC-19-0517.
This study aimed to evaluate liver involvement in patients with Carney complex (CNC) based on a large cohort and to analyze any germline PRKAR1A genotype-phenotype association of liver disease. The study included 83 patients with CNC, followed between 1995 and 2018 at a tertiary research center. We reviewed liver images, recorded types and number of lesions and analyzed per genotype: all patients were sequenced for the PRKAR1A gene. A total of 29/83 patients (24.0%) had liver radiological findings. Patients with liver lesion had a significantly higher rate of pathogenic variants detected in the PRKAR1A gene (72.4 vs 38.9%, P = 0.005, respectively). Patients with a pathogenic variant detected on germline PRKAR1A analysis had a higher risk for having a liver lesion compared with patients with wild-type (WT) PRKAR1A alleles (21/42 (50.0%) vs 8/41 (19.5%), respectively, P = 0.004). Among patients with liver lesions, those with a nonsense PRKAR1A pathogenic-variant had more liver lesions (7/7) than among those with other pathogenic-variant types (8/22, P = 0.001). In multivariable analysis, detection of liver lesion(s) was associated with an odds ratio of 5.2 for cardiac myxomas (95% CI 1.55-17.49, P = 0.008). In conclusion, patients with CNC, particularly with a PRKAR1A pathogenic variant, have a higher rate of liver lesions. Additionally, liver lesions are associated with a high risk for cardiac myxomas in this population.
本研究旨在通过大样本量评估卡尼综合征(CNC)患者的肝脏受累情况,并分析肝脏疾病相关的种系 PRKAR1A 基因型-表型关联。该研究纳入了 83 例 CNC 患者,这些患者于 1995 年至 2018 年在一家三级研究中心接受了随访。我们回顾了肝脏图像,记录了病变的类型和数量,并按基因型进行了分析:所有患者均对 PRKAR1A 基因进行了测序。83 例患者中有 29 例(24.0%)存在肝脏影像学表现。有肝脏病变的患者中,PRKAR1A 基因检测到致病性变异的比例明显更高(分别为 72.4%和 38.9%,P = 0.005)。与 PRKAR1A 野生型(WT)等位基因相比,种系 PRKAR1A 分析检测到致病性变异的患者发生肝脏病变的风险更高(分别为 21/42(50.0%)和 8/41(19.5%),P = 0.004)。在有肝脏病变的患者中,携带无义 PRKAR1A 致病性变异的患者肝脏病变更多(7/7),而携带其他致病性变异类型的患者肝脏病变较少(8/22,P = 0.001)。多变量分析显示,检测到肝脏病变与心脏黏液瘤的比值比为 5.2(95%CI 1.55-17.49,P = 0.008)。总之,CNC 患者,特别是携带 PRKAR1A 致病性变异的患者,肝脏病变发生率较高。此外,在该人群中,肝脏病变与心脏黏液瘤的发生风险较高相关。